{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:18:34Z","timestamp":1780514314172,"version":"3.54.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"National Key Research and Development Program of China","award":["2020YFC2008306"],"award-info":[{"award-number":["2020YFC2008306"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Lamotrigine is a new antiepileptic drug with substantial interindividual variability in its pharmacokinetics and therapeutic responses. This study aimed to develop population pharmacokinetic (PPK) models of lamotrigine and its N2-glucuronide metabolites for model-informed individualized therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A total of 353 plasma concentrations from Chinese patients with epilepsy receiving oral lamotrigine were used to develop a population PPK model using a nonlinear mixed effects modeling method. One- and two-compartment models were applied to the nonmetabolite and metabolite model, respectively. Forward addition and backward elimination were used to establish the final model. Model validation was performed using standard goodness-of-fit, bootstrap, visual predictive checks, and normalized prediction distribution errors. Finally, simulations were performed to propose lamotrigine dosages in different situations to achieve trough concentrations within the reference interval (2.5\u201315 mg\/L).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>For both final population PPK models, coadministration with valproic acid (VPA) or enzyme inducer, and body weight significantly affected lamotrigine clearance. The final models for lamotrigine clearance were \n                                    \n                                       \n                                    \n                                  and \n                                    \n                                       \n                                    \n                                  for nonmetabolite and metabolite models, respectively. The precision of the PPK parameters was acceptable, and the models exhibited good predictability. Monte Carlo simulations revealed that the lamotrigine dosage administered to patients combined with an enzyme inducer must be tripled that administered with VPA to reach the target trough concentration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Variability in the pharmacokinetics of lamotrigine is large. Coadministration of VPA or an enzyme inducer and body weight are the most important factors in lamotrigine clearance in Chinese patients with epilepsy. The developed population PPK models might support further optimization of lamotrigine dosing regimens.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001207","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T10:00:25Z","timestamp":1714125625000},"page":"649-657","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Population Pharmacokinetics of Lamotrigine and Its N2-Glucuronide Metabolite in Chinese Patients With Epilepsy"],"prefix":"10.1097","volume":"46","author":[{"given":"Hua","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China; and"},{"name":"Department of Pharmacy, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifeng","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/pr.120.019539","article-title":"Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options","volume":"72","author":"Loscher","year":"2020","journal-title":"Pharmacol Rev"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry","volume":"10","author":"Tomson","year":"2011","journal-title":"Lancet Neurol"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/epi4.12420","article-title":"Global survey of guidelines for the management of epilepsy in pregnancy: a report from the international league against epilepsy task force on women and pregnancy","volume":"5","author":"Tomson","year":"2020","journal-title":"Epilepsia Open"},{"issue":"suppl 1","key":"R7-20250603","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1177\/0883073897012001041","article-title":"Lamotrigine: pharmacokinetics","volume":"12","author":"Garnett","year":"1997","journal-title":"J Child Neurol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.ftd.0000245779.64080.30","article-title":"Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry","volume":"28","author":"Beck","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bcp.2011.12.032","article-title":"Lamotrigine is a substrate for OCT1 in brain endothelial cells","volume":"83","author":"Dickens","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2015.01.015","article-title":"The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2)","volume":"93","author":"Romermann","year":"2015","journal-title":"Neuropharmacology"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.seizure.2020.07.014","article-title":"Sources of lamotrigine pharmacokinetic variability: a systematic review of population pharmacokinetic analyses","volume":"82","author":"Methaneethorn","year":"2020","journal-title":"Seizure"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/FTD.0000000000000563","article-title":"A population pharmacokinetic-pharmacogenetic model of lamotrigine in Chinese children with epilepsy","volume":"40","author":"Chen","year":"2018","journal-title":"Ther Drug Monit"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00228-018-2414-8","article-title":"Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling","volume":"74","author":"Xu","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3389\/fphar.2019.00832","article-title":"Effects of comedication and genetic factors on the population pharmacokinetics of lamotrigine: a prospective analysis in Chinese patients with epilepsy","volume":"10","author":"Wang","year":"2019","journal-title":"Front Pharmacol"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"115017","DOI":"10.1016\/j.jpba.2022.115017","article-title":"Simultaneous determination of plasma lamotrigine, lamotrigine N2-glucuronide and lamotrigine N2-oxide by UHPLC-MS\/MS in epileptic patients","volume":"220","author":"Yang","year":"2022","journal-title":"J Pharm Biomed Anal"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0021-9673(01)88448-X","article-title":"Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, Lamotrigine","volume":"554","author":"Doig","year":"1991","journal-title":"J Chromatogr"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bcp.12984","article-title":"Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: influence of polymorphism of UDP-glucuronosyltransferases and drug transporters","volume":"82","author":"Milosheska","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-013-1606-5","article-title":"Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach","volume":"70","author":"Brzakovic","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","article-title":"Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data","volume":"43","author":"Hussein","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00228-012-1449-5","article-title":"Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients","volume":"69","author":"Singkham","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2125.1997.tb00133.x","article-title":"Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers","volume":"43","author":"Wootton","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/00912709922007949","article-title":"Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy","volume":"39","author":"Grasela","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0b013e31817fd4d4","article-title":"Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy","volume":"30","author":"Rivas","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/aps.2012.118","article-title":"Population pharmacokinetics of lamotrigine in Chinese children with epilepsy","volume":"33","author":"He","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00228-012-1311-9","article-title":"Population pharmacokinetics of lamotrigine in Indian epileptic patients","volume":"69","author":"Mallaysamy","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF03191157","article-title":"Lamotrigine and valproate pharmacokinetics interactions in epileptic patients","volume":"34","author":"Lalic","year":"2009","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00007691-200112000-00006","article-title":"Population pharmacokinetics of lamotrigine","volume":"23","author":"Chan","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/archneur.62.9.1432","article-title":"Effect of antiepileptic drug comedication on lamotrigine clearance","volume":"62","author":"Weintraub","year":"2005","journal-title":"Arch Neurol"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1016\/j.xphs.2020.05.030","article-title":"Dosing recommendations based on population pharmacokinetics of lamotrigine in Mexican adult patients with epilepsy","volume":"109","author":"Chavez-Castillo","year":"2020","journal-title":"J Pharm Sci"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00007691-199904000-00008","article-title":"Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications","volume":"21","author":"Armijo","year":"1999","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:05:01Z","timestamp":1748970301000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001207","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"2024-01-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}